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Abstract
Background: Daclizumab is a humanized monoclonal antibody against CD25 that modulates interleukin 2
signaling. The SELECT TRILOGY of clinical studies (SELECT/SELECTION/SELECTED) evaluated the safety and efficacy
of daclizumab in patients with relapsing-remitting multiple sclerosis (RRMS). We report the long-term safety and
efficacy of daclizumab 150 mg subcutaneous every 4 weeks in patients with RRMS in the SELECTED open-label
extension study.
Methods: An interim intent-to-treat analysis of all enrolled patients was performed in January 2014 for this
ongoing study.
Results: The SELECTED study enrolled 90 % of patients who completed SELECTION. In the safety and efficacy analysis
(N = 410), median treatment time in SELECTED was 25 months (range, <1–45). Adverse events (AEs) were reported in
76 % of patients, serious AEs (SAEs) excluding MS relapse in 16 %, and treatment discontinuation due to AEs including
multiple sclerosis (MS) relapse in 12 %. AEs were primarily of mild to moderate severity, and common AEs (≥10 %),
excluding MS relapse, were nasopharyngitis (12 %) and upper respiratory tract infection (12 %). Most commonly reported
SAEs (in ≥3 patients), excluding MS relapses, were increased serum hepatic enzymes, pneumonia, ulcerative colitis, and
urinary tract infection (<1 % each). Incidences of AE groups of interest include cutaneous events (28 %), cutaneous SAEs
(2 %), gastrointestinal SAEs (2 %), hepatic SAEs, (1 %) and malignancies (1 %). The incidence of AEs, SAEs, and
treatment-related study discontinuations did not increase over time and no deaths were reported. The
adjusted annualized relapse rate (95 % confidence interval (CI)) analyzed at 6-month intervals was 0.15 (0.10–0.
22) for weeks 97–120 and 0.15 (0.10–0.21) for weeks 121–144. In year 3, the adjusted mean (95 % CI) number of
new/newly enlarging T2 hyperintense lesions was
1.26 (0.93–1.72) and the mean (median) annualized change in brain volume was −0.32 % (−0.34 %).
Conclusions: The AE incidence did not increase with extension of therapy into year 3 in SELECTED; the safety
profile was similar to that previously observed. The clinical efficacy of daclizumab was sustained over the
3 years comprising the SELECT TRILOGY, although potential selection bias cannot be excluded.
Trial registration: Clinicaltrials.gov NCT01051349; first registered January 15, 2010.
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Background
Effective disease activity control in patients with relapsing-
remitting multiple sclerosis (RRMS) is critical for improved
long-term outcomes and requires long-term treatment.
Hence, it also is essential to establish the long-term safety
and efficacy of multiple sclerosis (MS) disease-modifying
therapies (DMTs).
Interleukin 2 (IL-2) signaling has a central role in
both immune system activation and regulation [1]. IL-2
receptors are expressed on a variety of immune cells,
including CD4+ and CD8+ T cells, regulatory T cells,
CD56bright natural killer cells, and myeloid dendritic
cells [2]. IL-2 signaling supports immune system acti-
vation through CD4+ and CD8+ T cell cytokine secre-
tion, T effector cell expansion, and CD8+ T cell and
CD56bright natural killer cell cytotoxicity, while also
supporting immune system regulation by promoting
regulatory T cell expansion and survival [2].
Daclizumab high-yield process (daclizumab)1 is a hu-
manized monoclonal antibody that modulates IL-2
signaling by binding to the IL-2 receptor alpha chain
(CD25), thereby inhibiting assembly of the high-affinity
IL-2 receptor (CD25/CD122/CD132) and shifting IL-2
signaling to cells that express the intermediate-affinity
IL-2 receptor (CD122/CD132) [2]. This transient shift
antagonizes proinflammatory activated T cells and leads
to the expansion of immunoregulatory CD56bright nat-
ural killer cells [2]. Daclizumab is hypothesized to inhibit
disease activity and slow disease progression by enhan-
cing endogenous mechanisms of immune tolerance
through expansion of immunoregulatory CD56bright nat-
ural killer cells and reducing early T cell activation [2].
The SELECT TRILOGY (SELECT [3], SELECTION [4],
SELECTED) of clinical studies was designed to evaluate
the efficacy and safety of daclizumab in patients with
RRMS. SELECT was a multicenter, randomized, double-
blind, phase 2 study that evaluated the efficacy and safety
of daclizumab 150 and 300 mg subcutaneous (SC) every
4 weeks for 1 year versus placebo [3]. In SELECTION, a
1-year double-blind extension of SELECT, placebo-treated
patients were randomized to daclizumab 150 or 300 mg
SC, and daclizumab-treated patients either continued
their previous dosage of daclizumab or underwent a 24-
week washout period followed by re-initiation of dacli-
zumab at their previous dose [4]. SELECTED is an
ongoing, open-label, extension study of SELECTION
that is being conducted to assess the long-term safety
and efficacy of daclizumab monotherapy (150 mg SC
every 4 weeks).
In SELECT, daclizumab 150 mg reduced adjusted an-
nualized relapse rate (ARR), disability progression, and
magnetic resonance imaging (MRI) lesion activity com-
pared with placebo [3]. Infections, cutaneous adverse
events (AEs), and hepatic enzyme elevations were more
common with daclizumab compared with placebo in
SELECT [3]. In SELECTION, the incidence of AEs was
similar to that observed in SELECT and efficacy was
maintained in the second year among patients receiving
continuous daclizumab treatment [4]. This paper reports
interim safety and efficacy data for an international co-




SELECTED is an ongoing, single-arm, open-label exten-
sion study to evaluate the long-term safety and efficacy
of daclizumab 150 mg SC every 4 weeks for up to
6.5 years from enrollment in patients with RRMS who
completed SELECT and SELECTION (Fig. 1). The study
is being conducted at 66 investigational sites in eight
countries: the Czech Republic, Germany, Hungary, India,
Poland, Russia, Ukraine, and the United Kingdom. The
first patient was enrolled and treated on 31 March
2010; enrollment is now completed and the study is
ongoing. The primary objective of SELECTED is to
Placebo 
SELECTED (N = 410)
Patients who did not enter SELECTION
completed the weeks 52–72 follow-up
visits as per SELECT protocol
Daclizumab 300 mg
Daclizumab 150 mg
Patients who did not enter SELECTED
completed the weeks 52–72 follow-up 
visits as per SELECTION protocol
Year 1 (weeks 0–52)
SELECT (N = 621)* SELECTION (N = 517)†















Fig. 1 SELECT TRILOGY study design. The dosing regimen for study drug (ie, placebo or daclizumab) was subcutaneous (SC) every 4 weeks in all
three studies of the SELECT TRILOGY [3, 4]. *Gold et al. [3]. †Giovannoni et al. [4]
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assess the safety of extended treatment with daclizumab
monotherapy in patients with RRMS; efficacy is being
assessed as a secondary objective.
Patient eligibility was determined at week 52 of
SELECTION, and this visit also served as the baseline
visit of SELECTED. At enrollment in SELECTED, patients
had previously received 1–2 years of treatment with dacli-
zumab 150 or 300 mg SC (with or without a washout with
total duration of 24 weeks comprised of the last 4 weeks
of SELECT and the 20 weeks of SELECTION). All eligible
patients received daclizumab 150 mg SC every 4 weeks,
and had clinic visits scheduled every 4 weeks for the first
12 weeks in the study, followed by clinic visits scheduled
every 12 weeks for up to 6 years of continuous treatment.
Patients
To be included in the study, patients must have com-
pleted 52 weeks of both SELECT and SELECTION, been
compliant with the SELECTION protocol, provided in-
formed consent for SELECTED, and met other general
eligibility criteria. Women of childbearing potential must
have agreed to practice effective contraception during
the study and for 4 months after their last dose of study
treatment. Key exclusion criteria included: a significant
change in medical status from a previous study that pre-
cluded administration of daclizumab, permanent discon-
tinuation of study treatment in SELECTION due to an
AE, enrollment in any other investigational drug study,
or ongoing treatment with any approved or experimental
DMT for MS. Eligibility criteria for SELECT and SELEC-
TION have been reported previously [3, 4].
Safety assessment
Safety and tolerability assessments included AE monitor-
ing, physical and neurological exams, vital signs, electro-
cardiograms, and clinical lab evaluations (hematology,
blood chemistry, liver function panel, and urinalysis).
For each AE, investigators rated its severity based on
guidance in the protocol and determined whether it
also met the regulatory criteria for a serious AE (SAE).
Patients who experienced a clinically significant
cutaneous AE (defined as rash, dermatitis, eczema,
acne, or folliculitis) were referred to a dermatologist.
Liver function testing (including alanine transaminase
[ALT], aspartate transaminase [AST], and total biliru-
bin) was performed monthly.
Efficacy assessment
Relapses were defined as new or recurrent neurological
symptoms, not associated with fever or infection, lasting
at least 24 h, and accompanied by new objective neuro-
logical findings upon examination by the neurologist. New
or recurrent neurological symptoms that evolved gradually
over months were considered disability progression, not
an acute relapse. New or recurrent neurological symptoms
that occurred less than 30 days following the onset of a
protocol-defined relapse were considered part of the same
relapse. Brain MRI scans were performed annually and
read for efficacy outcomes at a central reading institution
(Medical Image Analysis Center, Basel, Switzerland).
Statistical analysis
For both safety and efficacy parameters, changes from
baseline were evaluated based on the first dose of
daclizumab in either SELECT (patients randomized to
daclizumab in SELECT) or SELECTION (patients ran-
domized to placebo in SELECT and daclizumab in
SELECTION; Fig. 1).
Safety
The safety analysis was performed on all patients who
received at least one dose of daclizumab in SELECTED.
All treatment-emergent AEs during SELECTED were in-
cluded in the evaluation of safety. Treatment-emergent
AEs included any event that either occurred or worsened
in severity after the first dose of study treatment in
SELECTED up to 180 days after the last dose of daclizu-
mab. AEs were coded using the Medical Dictionary for
Regulatory Activities (MedDRA) Version 16.1. Hepatic
events were identified with the Standardized MedDRA
Query (SMQ) “drug related hepatic disorders.”
Efficacy
The intent-to-treat efficacy analysis was performed on
SELECTED patients starting from the first dose of dacli-
zumab treatment in patients randomized to daclizumab
in SELECT or first dose in SELECTION for patients
randomized to placebo in SELECT and daclizumab in
SELECTION. The ARR was calculated by tabulating the
total number of relapses experienced divided by the total
number of patient-years. The adjusted ARR was esti-
mated from a Poisson regression adjusted for the num-
ber of relapses in the year before study entry. Relapse
rates were also estimated by time interval from the first
dose of daclizumab received (0–24, 25–48, 49–72, 73–96,
97–120, 121–144 weeks). The adjusted mean number
of T2 hyperintense lesions during years 1, 2, and 3 of
daclizumab treatment was estimated from a negative
binomial regression adjusted for baseline number of
T2 hyperintense lesions. The annualized percentage
brain volume change (PBVC) was determined with
Structural Image Evaluation using Normalization of
Atrophy (SIENA) and was calculated as percentage
change divided by the number of days since the last
scan, multiplied by 365.25.
This report adheres to CONSORT guidelines.
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Results
Patients
Of all patients who completed SELECTION, 410 (90 %)
enrolled and were dosed with daclizumab in SELECTED
(Fig. 2). The safety and efficacy populations for this in-
terim analysis were the same, comprising all patients
who were dosed in SELECTED. SELECTED baseline pa-
tient characteristics are shown in Table 1. At the time of
this interim analysis, study enrollment was complete,
and all 410 enrolled patients had received at least one
dose of daclizumab in SELECTED. The median time on
daclizumab treatment in SELECTED was 25 (range, <1–45)
months (854 patient-years). Across the SELECT TRILOGY,
patients in SELECTED had received a median of 48 (range,
13–74) doses of daclizumab. At the time of the interim
analysis, 296 (72 %) patients had received more than 40
total doses and 168 (41 %) had received more than 50 total
doses. During the study period covered by the interim
analysis, 104 (25 %) patients discontinued treatment and
92 (22 %) patients withdrew from the study (Fig. 2).
Safety overview and incidence of AEs and SAEs
AEs were summarized by three time periods and overall.
The yearly incidence of AEs, SAEs, and AEs leading to
discontinuation did not increase over time and no
deaths were reported (Table 2). Forty-eight (12 %) pa-
tients discontinued treatment due to AEs (Table 3).
Common AEs that occurred in 10 % of patients or more
were MS relapse (22 %), nasopharyngitis (12 %), and
upper respiratory tract infection (12 %; Table 4). The
most frequently reported SAEs excluding MS relapse,
were hepatic enzyme elevations, pneumonia, ulcerative
colitis, and urinary tract infection (each in three patients
[each less than 1 %]; Table 5).
Infections
Infections were reported in 50 % of patients, with ser-
ious infections reported in 3 %. The incidence of infec-
tions did not increase over time, reported in 34 % of
patients during weeks 1–48, 30 % during weeks 49–96,
and 24 % during weeks 97 and above. The majority of
infections were mild or moderate in severity. Less than
1 % of patients discontinued treatment due to infections.
The common AEs of infections (occurring in 10 % or
more of patients) were nasopharyngitis and upper re-
spiratory tract infections. Serious infections occurring in
two or more patients were pneumonia, urinary tract in-
fection, and bronchitis (Table 6). There were two reports
of potential opportunistic infections; one non-serious
case of vulvovaginal candidiasis, which was treated with
clotrimazole cream and resolved in 1 week, and one case
of pulmonary tuberculosis, which occurred after receiv-
ing daclizumab for 2.5 years (33 total doses) in a Ukrain-
ian patient where tuberculosis is endemic [5]; treatment
was discontinued for this patient and the patient with-
drew from the study. Daclizumab was temporarily inter-
rupted in two patients due to serious infections;




410 patients enrolled and
dosed in SELECTED
318 patients continuing in
SELECTED as of
20 January 2014
104 patients discontinued treatment:
 • 48 due to AEs
 • 40 due to consent withdrawn
 • 6 due to non-compliance
 • 6 due to other
 • 2 due to investigator decision
 • 2 lost to follow-up
 • 0 died
92 patients withdrew from the study:
 • 40 due to AEs
 • 36 due to consent withdrawn
 • 5 due to non-compliance
 • 5 due to other
 • 3 due to investigator decision
 • 3 lost to follow-up
 • 0 died
Fig. 2 SELECTED trial profile. Since the duration of SELECTED is over
5 years, based on first patient dosed date of 31 March 2010, no patient
had completed the study as of the data cutoff for this manuscript. AE
Adverse event




Age, years, mean (SD) 38 (9)
Female, % 62
No. of relapses in prior study, mean (SD)a 0.2 (0.5)
Range 0–3
EDSS score, mean (SD) 2.7 (1.3)
Range 0–6
No. of Gd+ lesions, mean (SD) 0.2 (1.0)
Range 0–12
Patients with ≥1 Gd+ lesion(s), n (%) 40 (10)
No. of T2 hyperintense lesions, mean (SD) 46.3 (36.5)
Range 0–194
T2 hyperintense lesion volume, mm3, median 3868
T1 hypointense lesion volume, mm3, median 751
Months on treatment, medianb 25
Range <1–45
Doses, mean (SD) 27.7 (10.8)
Median 28.0
Range 1–49
EDSS Expanded Disability Status Scale, Gd+ Gadolinium-enhancing, SC
Subcutaneous, SD Standard deviation
aIncludes all relapses in SELECTION, whether in the treatment period, randomized
washout phase, or follow-up period, either confirmed or not confirmed by an
independent neurology evaluation committee
bTime on treatment in days was derived as (date of last dose) – (date of first
dose in SELECTED) + 1
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the latter was treated with clavulanate/amoxicillin, clari-
thromycin, and levofloxacin. In both cases, the events
resolved and study treatment was resumed.
Cutaneous AEs
Cutaneous events were reported in 28 % of patients,
with serious cutaneous AEs in 2 %. The only cutaneous
SAE reported in more than one patient was urticaria (in
two patients; Table 6). One serious cutaneous AE was
reported as Stevens-Johnson syndrome by the treating
neurologist, but the diagnosis was not supported by the
case details per the central independent dermatologist
and the local site dermatologist assessments. The case
did not meet the standard diagnostic criteria for
Stevens-Johnson syndrome, as it was moderate in inten-
sity, localized, lacked any bullous or necrotic skin le-
sions, and had no areas of loss, including full-thickness
of the epidermis.
Table 2 Summary of AEs in SELECTED by time intervals and overall
AE, n (%) Daclizumab 150 mg SC
Weeks 1–48a Weeks 49–96b Week 97 and abovec Overall
(n = 410) (n = 387) (n = 279) (N = 410)
All AEs 245 (60) 222 (57) 126 (45) 312 (76)
AEs by severityd
Mild 122 (30) 96 (25) 45 (16) 101 (25)
Moderate 110 (27) 115 (30) 70 (25) 178 (43)
Severe 13 (3) 11 (3) 11 (4) 33 (8)
All SAEs 53 (13) 47 (12) 34 (12) 105 (26)
SAEs (excluding MS relapse) 23 (6) 26 (7) 20 (7) 66 (16)
AEs leading to treatment discontinuation 22 (5) 17 (4) 9 (3) 48 (12)
Death 0 0 0 0
AE Adverse event, MS Multiple sclerosis, SAE Serious adverse event, SC Subcutaneous
aWeeks 1–48 of SELECTED represents the second year of daclizumab treatment in patients who were newly treated with daclizumab in SELECTION [4] and the
third year of treatment in patients originally treated with daclizumab in SELECT [3]
bWeeks 49–96 represents the third year of daclizumab treatment in patients who were newly treated with daclizumab in SELECTION [4] and the fourth year of
treatment in patients originally treated with daclizumab in SELECT [3]
cWeek 97 and above represents the fourth year and above of daclizumab treatment in patients who were newly treated with daclizumab in SELECTION [4] and
the fifth year and above of treatment in patients originally treated with daclizumab in SELECT [3]
dPatients counted in the category of maximum severity experienced in the time interval
Table 3 AEs leading to treatment discontinuation in three or
more patients
AE, n (%) Daclizumab 150 mg SC
(N = 410)
Any AE leading to treatment discontinuation 48 (12)
Investigations 19 (5)
Increased ALT 11 (3)
Increased AST 5 (1)
Increased hepatic enzyme 4 (<1)
Skin and subcutaneous tissue disorders 12 (3)
Allergic dermatitis 3 (<1)
Gastrointestinal disorders 4 (<1)
Colitis 3 (<1)
Hepatobiliary disorders 4 (<1)
Infections and infestations 4 (<1)
AE Adverse event, ALT Alanine transaminase, AST Aspartate transaminase,
SC Subcutaneous
Table 4 Common AEs (occurring in 5 % of patients or more)a
AE, n (%) Daclizumab 150 mg SC
(N = 410)
MS relapse 89 (22)
Nasopharyngitis 51 (12)
Upper respiratory tract infection 49 (12)
Increased ALT 37 (9)
Pharyngitis 35 (9)
Headache 33 (8)
Urinary tract infection 31 (8)
Back pain 29 (7)
Increased AST 28 (7)
Rash 27 (7)
Diarrhea 22 (5)
Allergic dermatitis 21 (5)
Viral respiratory tract infection 20 (5)
Bronchitis 19 (5)
Oral herpes 19 (5)
AE Adverse event, ALT Alanine aminotransferase, AST Aspartate aminotransferase,
MS Multiple sclerosis, SC Subcutaneous
aAEs in ≥5 % of patients by Medical Dictionary for Regulatory Activities
Preferred Term
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The most common cutaneous AEs were rash (7 %),
allergic dermatitis (5 %), and eczema (3 %); the yearly in-
cidence did not increase over time. The majority of pa-
tients experienced cutaneous AEs that were mild or
moderate in severity; four (less than 1 %) patients expe-
rienced severe cutaneous AEs. Cutaneous events led to
discontinuation of study treatment in 3 % of patients.
Hepatic AEs
Adverse events of drug-related hepatic disorders, per
SMQ, were reported in 15 % of the patients with SAEs
reported in 1 % (Table 6). Overall, the incidence of ALT
or AST elevations ≥3 × upper limit of normal (ULN) was
9 % and ALT or AST elevations >5 × ULN was 4 %. Two
patients had liver transaminases elevations >3 × ULN
with concurrent elevation of bilirubin values >2 × ULN.
One of these patients experienced toxic liver disease
considered to be secondary to treatment with valproate
approximately 2.5 months after discontinuing study
treatment. The second patient experienced jaundice with
elevated liver function tests approximately 8 weeks after
study treatment discontinuation following treatment of a
skin event with herbal supplements and the use of influ-
enza medication containing paracetamol.
Gastrointestinal AEs
Gastrointestinal AEs, defined as AEs in the MedDRA
System Organ Class of Gastrointestinal Disorders, were
reported in 16 % of patients, with the majority of pa-
tients experiencing events that were mild or moderate in
severity. The incidence of serious gastrointestinal AEs
was 2 %. The incidence of gastrointestinal events that
led to discontinuation of study treatment was less than
1 %. Six (1 %) patients reported serious inflammatory
gastrointestinal events, including three cases of ulcera-
tive colitis and one case each of colitis, Crohn’s
disease, and hemorrhagic enterocolitis. Treatment
Table 5 SAEs occurring in two or more patientsa
SAE, n (%) Daclizumab 150 mg SC
(N = 410)
Any SAE 105 (26)
MS relapse 47 (11)
Increased hepatic enzyme 3 (<1)
Pneumonia 3 (<1)
Ulcerative colitis 3 (<1)
Urinary tract infection 3 (<1)
Bronchitis 2 (<1)
Intervertebral disc disorder 2 (<1)
Lower limb fracture 2 (<1)
Lymphadenopathy 2 (<1)
Urticariab 2 (<1)
MS Multiple sclerosis, SAE Serious adverse event, SC Subcutaneous
aSAEs in two or more patients by Medical Dictionary for Regulatory Activities
Preferred Term
bOther cutaneous SAEs are presented in Table 6
Table 6 Summary of serious infections, serious cutaneous AEs,
serious hepatic AEs, and hepatic laboratory abnormalities
n (%) Daclizumab
150 mg SC
Any serious infectiona (n = 410) 13 (3)
Pneumonia 3 (<1)
Urinary tract infection 3 (<1)
Bronchitis 2 (<1)
Clostridium difficile colitis 1 (<1)
Diverticulitis 1 (<1)
Gastrointestinal infection 1 (<1)
Hepatitis C 1 (<1)
Infectious mononucleosis 1 (<1)
Upper respiratory tract infection 1 (<1)
Any serious cutaneous AEb (n = 410) 8 (2)
Urticaria 2 (<1)
Allergic dermatitis 1 (<1)
Erythrodermic psoriasis 1 (<1)
Photodermatitis 1 (<1)
Psoriasis 1 (<1)
Stevens-Johnson syndromec 1 (<1)
Toxic skin eruption 1 (<1)
Any serious hepatic AEd (n = 410) 5 (1)
Hepatic enzyme increased 3 (<1)
Autoimmune hepatitis 1 (<1)
Gamma-glutamyltransferase increased 1 (<1)
Hepatic laboratory abnormalities (n = 409)
ALT or AST
≥3 × ULN 37 (9)
>5 × ULN 18 (4)
>10 × ULN 11 (3)
Elevation in ALT or AST≥3 × ULN with concurrent
total bilirubin >2 × ULN
2 (<1)e
AE Adverse event, ALT Alanine aminotransferase, AST aspartate
aminotransferase, SC Subcutaneous, ULN Upper limit of normal
Patients counted once at each level of summarization
aSerious infections defined as SAEs in the Medical Dictionary for Regulatory
Activities (MedDRA) System Organ Class (SOC) Infections and Infestations
bSerious cutaneous AEs defined as SAEs in the MedDRA SOC Skin and
Subcutaneous Tissues Disorders
cOne case was reported as Stevens-Johnson syndrome but the diagnosis was
not supported by the case details per the central independent dermatologist
and the local site dermatologist (see text for details)
dSerious hepatic AEs defined as SAEs under the Standarized MedDRA Query
(SMQ) of drug-related hepatic disorders
eNo patients had concurrent elevations of ALT or AST ≥3 × ULN and total
bilirubin >2 × ULN in the clinical database at the time of the interim analysis;
however, two patients experienced such abnormalities either while
hospitalized or after the data cutoff. In both cases, other factors as reported in
the text that could have contributed to the events were noted
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included discontinuation of study treatment and
standard therapies for colitis, including mesalazine,
sulfasalazine, corticosteroids, and azathioprine. The
majority of AEs resolved or were stable with no flares
following discontinuation of study treatment and/or
treatment with standard therapies for colitis.
Malignancies
Based on the search using the SMQ of “malignant or un-
specified tumors” and medical review, there were four
(1 %) patients reported with events classified as malig-
nant neoplasms, one each of: (a) breast cancer, diag-
nosed following treatment with placebo for 1 year and
daclizumab 150 mg SC for 3 years and 2 months; (b)
basal cell carcinoma, diagnosed following treatments
with placebo for 1 year, daclizumab 300 mg SC for 1 year,
and daclizumab 150 mg SC for 2 years and 9 months;
(c) anal cancer, diagnosed following treatment with
daclizumab 300 mg SC for 1 year, washout and re-
initiation of daclizumab 300 mg SC for 1 year, and dacli-
zumab 150 mg SC for approximately 5 months; and (d)
pulmonary carcinoid tumor, diagnosed after treatment
with placebo for 1 year, daclizumab 300 mg SC for 1 year,
and daclizumab 150 mg SC for approximately 2 years. Of
these cases of malignancy, anal cancer and pulmonary car-
cinoma were considered related to study treatment by the
investigators. Overall, there was no observed pattern to
the type of malignancies.
Efficacy
The adjusted ARR analyzed at 6-month intervals from
the first dose of daclizumab was 0.21 (95 % confidence
interval (CI), 0.16–0.29) for weeks 0–24 and decreased
to 0.15 (95 % CI, 0.10–0.21) by the weeks 121–144 inter-
val (Fig. 3). The adjusted mean (95 % CI) number of
new/newly enlarging T2 hyperintense lesions was 1.95
(1.60–2.37) in year 1 and decreased to 1.26 (0.93–1.72)
by year 3 of treatment with daclizumab (Fig. 4). The mean
(median) annualized PBVC was −0.77 % (−0.63 %) in year
1 and decreased to −0.32 % (−0.34 %) by year 3 of treat-
ment with daclizumab (Fig. 5).
Discussion
These interim findings from the SELECTED extension
study indicate that although AEs continued to occur
during the 3rd year of patient treatment, there was no
significant increase in the incidence of AEs and the
safety profile remained consistent over time during
extended treatment with daclizumab 150 mg SC in
SELECTED, and that efficacy benefits were maintained
for up to 3 years of treatment. The overall safety profile
of daclizumab 150 mg SC in SELECTED was consistent
with that observed in the previous studies, SELECT and
SELECTION [3, 4] and in the 2- to 3-year, active-control
phase 3 study of daclizumab 150 mg compared with
interferon beta-1a [6]. In SELECT, infections, cutaneous
AEs, and hepatic enzyme elevations were more common
in daclizumab-treated patients than in placebo-treated
patients [3], and the incidence of AEs did not increase
in the second year of treatment with daclizumab while in
SELECTION [4]. Similarly, 28 % in the safety population
in this analysis reported cutaneous events compared with
13 % of patients in the placebo group in SELECT over a
52-week treatment period [3].




































SELECT* Weeks from first dose of daclizumab
n = 196
Fig. 3 Adjusted annualized relapse rate (ARR) by 6-month intervals.
Results from the SELECT placebo group have been published
previously [3]. Adjusted ARR in SELECTED was estimated from a
Poisson regression adjusted for the number of relapses in the
year before study entry. Rates were estimated by time interval
from the first dose of daclizumab received. *Gold et al. [3]




















































Fig. 4 Adjusted mean number of new/newly enlarging T2 hyperintense
lesions. Results from the SELECT placebo group have been published
previously [3]. The adjusted mean number of T2 hyperintense lesions
was estimated from a negative binomial regression adjusted for baseline
number of T2 hyperintense lesions. *Gold et al. [3]
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The yearly incidences of serious infections, cutaneous
events, and liver enzyme abnormalities in this interim
analysis of up to 3 additional years of daclizumab
150 mg SC treatment in SELECTED were similar to
those observed in the first and second years of treatment
in previous studies [3, 4], suggesting there was no appar-
ent negative cumulative impact of long-term daclizumab
treatment, especially with respect to hepatic function.
Based on available data, there does not appear to be an
increased rate of malignancy with extended daclizumab
treatment; however, there is no comparator arm in this
long-term follow-up. AEs associated with daclizumab
treatment were generally self-limited or responsive to
standard medical care. MS relapses categorized as SAEs
were reported in 8 %, 6 % and 5 % of patients in Years 1,
2, and 3 of this study, respectively, compared with 21 %
of patients treated with placebo during the treatment
period of the SELECT study (unpublished observations,
Biogen). One of the criteria used to define a SAE was
any event requiring hospitalization or prolongation of
hospitalization, and, thus, any such event was classified
as an SAE. Adjusted ARR, the number of new/newly
enlarging T2 hyperintense lesions, and the rate of brain
volume loss remained low in year 3 of daclizumab
150 mg SC treatment, showing that the efficacy of dacli-
zumab 150 mg SC is maintained for up to 3 years of
treatment. Across the outcome measures evaluated, clin-
ical and MRI MS disease activity in the third year of
treatment with daclizumab 150 mg SC was consistently
lower than that observed in the placebo group in year 1
in SELECT [3].
Limitations generally associated with long-term exten-
sion studies should be taken into consideration when
interpreting the interim results of this study. Most im-
portantly, SELECTED was an open-label study without a
control group, similar to other open-label long-term
extension studies [7, 8]. Secondly, despite the fact that
there was a high re-enrollment rate from study to study
in the SELECT TRILOGY [4] and a low rate of discon-
tinuation due to AEs, patients non-responsive to treat-
ment or those who are doing less well on treatment may
have chosen not to continue to SELECTED, resulting in
possible selection bias, favoring the retention of patients
who either respond to or better tolerate daclizumab [4].
While this interim analysis may be affected by selection
bias, any potential selection bias may be partially offset
once the 6-year treatment period and 6-month postdosing
safety follow-up for SELECTED are complete.
Previous patient exposure to the study drug was variable,
ranging from 1–2 years treatment prior to SELECTED,
either at the 300 mg or 150 mg dose, with or without a
24-week washout period at the beginning of year 2. This
heterogeneity limits the strength of the efficacy conclu-
sions; however, the results were consistent with analyses
performed on the subset of SELECTED patients continu-
ously treated with daclizumab 150 mg [9]. This variability
may be more reflective of clinical practice rather than a
typical clinical trial. Although conclusions regarding effi-
cacy are limited by the lack of a control group, the effects
of daclizumab on clinical and radiologic disease activity
observed in year 1 were maintained for up to 3 years of
treatment.
Conclusions
The evaluation of long-term safety and efficacy of DMTs
is important given the chronic nature of MS and the
need for long-term treatment. Overall, the SELECTED
findings provide evidence that risks associated with
daclizumab were consistent with previous clinical trial
experience with extended treatment, and reductions in
MS disease activity on clinical and MRI outcomes were
preserved over 3 years of treatment with daclizumab
150 mg SC. These findings suggest that daclizumab
150 mg SC may have a favorable benefit-risk profile
for extended treatment in patients with RRMS. The
SELECTED study is ongoing and the SELECT TRILOGY
of clinical studies will provide data on up to 8 years of
treatment, to inform the long-term safety and efficacy pro-
file of daclizumab 150 mg SC monotherapy in patients
with RRMS.
Endnotes
1Daclizumab HYP, approved as Zinbryta™, has a differ-
ent form and structure from an earlier form of daclizumab
(Zenapax).













































Fig. 5 Mean (median) annualized percentage brain volume change
(PBVC). Results from the SELECT placebo group have been published
previously [3]. The annualized PBVC was determined with Structural
Image Evaluation using Normalization of Atrophy (SIENA) and was
calculated as percentage change divided by the number of days since
the last scan multiplied by 365.25. For PBVC endpoints, patients with
any post-baseline magnetic resonance imaging assessment in the
efficacy population were included in the analysis. *Gold et al. [3]
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